Brightonix Imaging said that the positron tomography (PET) scanner, which is being developed with the support of the Korea Medical Device Development Fund, received a lot of attention and response from participants at the 2022 Annual Congress of the European Association of Nuclear Medicine (EANM 2022) held at the Barcelona International Convention Center from the 15th to the 19th October.
Brightonix Imaging, which operated the exhibition booth at EANM 2022, the world's largest nuclear medicine and molecular imaging society (6800 registered people in 2022), introduced Korea's advanced nuclear medicine imaging equipment and software technology.
Lecanemab, a new drug candidate for Alzheimer's dementia jointly developed by Biogen and Ezai, recently showed good results of improved cognitive function, in phase 3 of clinical trial. This has drawn attention to the importance of brain PET scans that provide accurate information on the distribution of amyloid and tau protein in patients with Alzheimer's dementia.
The company said, "Because PET-CT specialized in cancer diagnosis requires billions of won and a very large footprint, interest in the brain-dedicated PET system is increasing. Our multi-purpose high-resolution PET is designed to take brain scans in a sitting or lying position compared to other products, and we had more than 1,000 visitors at our booth over the three days."
Jae Sung Lee, CEO of Brightonix Imaging, said, "The high-resolution multipurpose PET system, which reduces the installation space and cost while providing higher performance, will help conquering Alzheimer's dementia by increasing the accuracy of early diagnosis and treatment effect estimation."
Dr. Andrew Lonergan, who oversees the exhibition of the Brightonix Imaging in European conferences, said, "It is very unusual that the global sales and service network base are built just in days by such active partnership proposals from distributors and service providers of medical imaging equipment in Europe and major Asian countries."